Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2005-04-12
2005-04-12
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S008100, C514S012200, C530S350000
Reexamination Certificate
active
06878370
ABSTRACT:
The present invention concerns a chemically modified TNF-α, and a pharmaceutical composition and a vaccine composition containing the chemically modified TNF-α which are useful for combating overproduction of native TNF-α.
REFERENCES:
patent: 4414147 (1983-11-01), Klibanov et al.
patent: 2 677 654 (1991-06-01), None
patent: 2 773 156 (1997-12-01), None
patent: WO 9421288 (1994-09-01), None
patent: WO 9421288 (1994-09-01), None
Tsunoda et al. (Mar. 1998), 56(3), pp. 573-578, Japanese Journal of clinical medicine.
Zagury Daniel
Zagury Jean-François
Browdy and Neimark PLLC
Mertz Prema
Neovacs
LandOfFree
Chemically modified TNF-α does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically modified TNF-α, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically modified TNF-α will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368473